跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 10 天前精选AI 评分65

Beam 表示基因编辑疗法在二期临床试验中取得成功

Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study

AI 导读

Beam Therapeutics 宣布其基因编辑疗法在二期临床试验中取得成功,可能成为治疗镰状细胞病的第三种单次疗法。

推荐理由

详细报道了基因编辑疗法在二期临床试验中的成功结果,为该疗法的进一步发展提供了重要依据。

正文 · 原文

Beam Ther­a­peu­tics an­nounced Tues­day that its base-edit­ed sick­le cell ther­a­py suc­ceed­ed in a clin­i­cal tri­al, mean­ing a third one-time ther­a­py for the dis­ease may soon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news